Ładuje się......
Mechanisms of action of CD20 antibodies
Therapeutic monoclonal antibodies (mAbs) that target the CD20 antigen on B cells are successfully used in the clinic for the depletion of B cells to treat various forms of cancer and autoimmune diseases. The first CD20 mAb, approved by the FDA in 1998, was rituximab (RTX) and since then it has been...
Zapisane w:
| Główni autorzy: | , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
e-Century Publishing Corporation
2012
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3512181/ https://ncbi.nlm.nih.gov/pubmed/23226614 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|